TY  - JOUR
AU  - Ribera, Josep-Maria
AU  - Garcia, Olga
AU  - Moreno, Maria-Jose
AU  - Barba, Pere
AU  - Garcia-Cadenas, Irene
AU  - Mercadal, Santiago
AU  - Montesinos, Pau
AU  - Barrios, Manuel
AU  - Gonzalez-Campos, Jose
AU  - Martinez-Carballeira, Daniel
AU  - Gil, Cristina
AU  - Ribera, Jordi
AU  - Vives, Susana
AU  - Novo, Andres
AU  - Cervera, Marta
AU  - Serrano, Josefina
AU  - Lavilla, Esperanza
AU  - Abella, Eugenia
AU  - Tormo, Mar
AU  - Amigo, Maria-Luz
AU  - Artola, Maria-Teresa
AU  - Genesca, Eulalia
AU  - Bravo, Pilar
AU  - Garcia-Belmonte, Daniel
AU  - Garcia-Guiñon, Antoni
AU  - Hernandez-Rivas, Jesus-Maria
AU  - Feliu, Evarist
PY  - 2019
DO  - 10.1002/cncr.32156
UR  - http://hdl.handle.net/10668/13867
T2  - Cancer
AB  - Disease recurrence occurs in 20% to 40% of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who are treated with chemotherapy and tyrosine kinase inhibitors (TKIs). In the current study, the authors report the...
LA  - en
PB  - Wiley
KW  - Philadelphia chromosome-positive acute lymphoblastic leukemia
KW  - Clinical disease recurrence
KW  - Molecular disease recurrence
KW  - Outcome
KW  - Adolescent
KW  - Adult
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Hematopoietic Stem Cell Transplantation
KW  - Humans
KW  - Imatinib Mesylate
KW  - Incidence
KW  - Middle Aged
KW  - Neoplasm Recurrence, Local
KW  - Precursor Cell Lymphoblastic Leukemia-Lymphoma
KW  - Protein Kinase Inhibitors
KW  - Survival Analysis
KW  - Treatment Outcome
KW  - Young Adult
TI  - Incidence and outcome after first molecular versus overt recurrence in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia included in the ALL Ph08 trial from the Spanish PETHEMA Group.
TY  - research article
VL  - 125
ER  -